Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/complete-pathological-response-of-colorectal-liver-metastases-after-98oysuIeH0
References (40)
-
R. Church, J. Fleshman, D. Dietz, S. Strasberg, SR Bramhall (2003)
Liver resection for colorectal metastases.Annals of the Royal College of Surgeons of England, 86 5
-
L. Alexander, L. Saltz (2007)
Updated Efficacy Results from XELOX1/NO16966, a Randomized Phase 3 Trial inFirst-Line Metastatic Colorectal Cancer, 7
-
L. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T. Yang, J. Cassidy (2007)
Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancerJournal of Clinical Oncology, 25
-
R. Adam (2003)
Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.Annals of oncology : official journal of the European Society for Medical Oncology, 14 Suppl 2
-
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
-
C. Willett, Y. Boucher, E. Tomaso, D. Duda, L. Munn, Ricky Tong, D. Chung, D. Sahani, S. Kalva, S. Kozin, M. Mino, K. Cohen, D. Scadden, A. Hartford, A. Fischman, Jeffrey Clark, D. Ryan, A. Zhu, L. Blaszkowsky, Helen Chen, P. Shellito, G. Lauwers, R. Jain (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNature Medicine, 10
-
N. Minagawa, Y. Nakayama, K. Hirata, K. Onitsuka, Yuzuru Inoue, N. Nagata, H. Itoh (2002)
Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer.Anticancer research, 22 5
-
Hyun Kim, C. Jung, Kihyun Kim, J. Ahn, W. Kim, Kwan-A Park, Y. Ko, W. Kang, Keunchil Park (2006)
Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 24
-
F. Kabbinavar, J. Hambleton, R. Mass, H. Hurwitz, E. Bergsland, S. Sarkar (2005)
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
-
J. Tabernero, Yves Humblet, E. Cutsem, Javier Sastre, A. Cervantes, J. Laethem, Patrick Soulié, S. Corretgé, M. Mueser, A. Gramont (2004)
An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
-
Y Fong, A Cohen, JG Fortner (1997)
Liver resection for colorectal metastasesJ Clin Oncol, 15
-
G. Ballantyne, J. Quin (1993)
Surgical treatment of liver metastases in patients with colorectal cancerCancer, 71
-
H. Bismuth, R. Adam, F. Lévi, C. Farabos, F. Waechter, D. Castaing, P. Majno, L. Engerran (1996)
Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.Annals of surgery, 224 4
-
A. Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortés-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Bail, C. Louvet, D. Hendler, F. Braud, Colin Wilson, F. Morvan, A. Bonetti (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 16
-
C. Pozzo, M. Basso, A. Cassano, M. Quirino, G. Schinzari, N. Trigila, M. Vellone, F. Giuliante, G. Nuzzo, C. Barone (2004)
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 15 6
-
Pignon Jp, M. Ducreux (2001)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 344 4
-
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
-
E. Rubio, Y. Humblet, J. Tabernero, E. Cutsem, A. Cervantes, T. André, P. Soulié, S. Corretgé, O. Kisker, A. Gramont (2005)
Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.Journal of Clinical Oncology, 23
-
M. Delgado, J. Spano, D. Khayat (2007)
Cetuximab plus irinotecan in refractory colorectal cancer patientsExpert Review of Anticancer Therapy, 7
-
G. Leonard, B. Brenner, N. Kemeny (2005)
Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 9
-
J Tabernero, E Cutsem (2004)
An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR)Preliminary results. Proc Am Soc Clin Oncol 2004,, 23
-
A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, M. Thun (2007)
Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 57
-
FL Greene (2002)
Updating the Strategies in Cancer StagingAmerican College of Surgeons Bulletin, 87
-
S. Berry, E. Cutsem, A. Kretzschmar, M. Michael, F. Rivera, M. Dibartolomeo, M. Mazier, N. Andre, D. Cunningham (2008)
Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEATJournal of Clinical Oncology, 26
-
E. Cutsem, M. Nowacki, I. Láng, S. Cascinu, I. Shchepotin, J. Maurel, P. Rougier, D. Cunningham, J. Nippgen, C. Köhne (2007)
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trialJournal of Clinical Oncology, 25
-
V. Ferrari, F. Valcamonico, V. Amoroso, L. Vassalli, S. Grisanti, P. Marpicati, E. Simoncini, G. Rangoni, G. Marini (2005)
FAFOXIRI: A phase II trial of an alternating regimen of irinotecan/5-fluoruracil/folinic acid and oxaliplatin/5-fluoruracil/folinic acid in metastatic colorectal cancerJournal of Clinical Oncology, 23
-
A. Sobrero, P. Bruzzi (2005)
Bevacizumab plus fluorouracil: the value of being part of a developing story.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
-
A. Falcone, G. Masi, F. Loupakis, E. Vasile, A. Ciarlo, D. Cavaciocchi, D. Amoroso, M. Puglisi, E. Fea, I. Brunetti (2008)
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. groupJournal of Clinical Oncology, 26
-
S. Berry (2008)
Just say die.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 1
-
J. Cassidy, D. Cunningham, S. Berry, F. Rivera, S. Clarke, A. Kretzschmar, E. Díaz-Rubio, E. Cutsem, L. Saltz (2008)
Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966Journal of Clinical Oncology, 26
-
M. Somerfield, Kaitlin Einhaus, K. Hagerty, M. Brouwers, J. Seidenfeld, G. Lyman (2008)
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 24
-
(2003)
Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) -
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 350 23
-
G. Folprecht, A. Grothey, S. Alberts, H. Raab, C. Köhne (2005)
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.Annals of oncology : official journal of the European Society for Medical Oncology, 16 8
-
A Falcone, S Ricci (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancerJ Clin Oncol, 25
-
F. Greene (2002)
The American Joint Committee on Cancer: updating the strategies in cancer staging.Bulletin of the American College of Surgeons, 87 7
-
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crinò, G. Benedetti, W. Evangelista, L. Fanchini, E. Cortesi, V. Picone, S. Vitello, S. Chiara, C. Granetto, G. Porcile, L. Fioretto, C. Orlandini, M. Andreuccetti, G. Masi (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 13
-
C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, D. Mery-mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet, A. Gramont (2023)
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 41
-
L. Saltz, J. Douillard, N. Pirotta, M. Alakl, G. Gruia, Lucile Awad, G. Elfring, P. Locker, L. Miller (2001)
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.The oncologist, 6 1
-
S. Giacchetti, M. Itzhaki, G. Gruia, R. Adam, R. Zidani, F. Kunstlinger, S. Brienza, E. Alafaci, F. Bertheault-Cvitkovic, C. Jasmin, M. Reynés, H. Bismuth, Misset Jl, F. Lévi (1999)
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.Annals of oncology : official journal of the European Society for Medical Oncology, 10 6
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by Springer-Verlag
- Subject
- Medicine & Public Health; Biomedicine general; Oncology
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-008-0094-5
- Publisher site
- See Article on Publisher Site
Abstract
The vast majority of colorectal cancer patients who present with liver metastases are not initially candidates for hepatic resection. Although the combination of systemic chemotherapy and liver surgery can convert a significant proportion of patients from a palliative situation to a potentially curative situation, the majority of initially unresectable liver metastases do not respond sufficiently to initial chemotherapy to become resectable. More recently the addition of biologic agents (bevacizumab or cetuximab) to cytotoxic chemotherapy has increased the rate of tumor response, suggesting that the addition of these agents could improve resectability rate. Here we report the clinical case of a complete pathological response (pCR) in a 67-year-old male affected by metastatic colorectal cancer, with initially unresectable liver metastases, after treatment with chemotherapy and bevacizumab.
Journal
Targeted Oncology – Springer Journals
Published: Oct 30, 2008